<DOC>
	<DOCNO>NCT02708680</DOCNO>
	<brief_summary>The purpose study determine safety tolerability entinostat use combination atezolizumab patient Advanced Triple Negative Breast Cancer ( aTNBC ) . Additionally purpose study assess effective entinostat atezolizumab combination patient aTNBC .</brief_summary>
	<brief_title>Randomized Phase 2 Study Atezolizumab Entinostat Patients With aTN Breast Cancer With Phase 1b Lead In</brief_title>
	<detailed_description>SNDX-275-0602 Phase 1b/2 study evaluate combination entinostat plus atezolizumab patient aTNBC . The study 2 phase : open-label Dose Determination Phase ( Phase 1b ) follow Expansion Phase ( Phase 2 ) . The Expansion Phase evaluate efficacy safety entinostat administer RP2D atezolizumab patient aTNBC randomize , double-blind , placebo-controlled setting . Up 88 evaluable patient anticipate study complete phase evaluation ( 18 patient Phase 1b , 70 patient Phase 2 ) . Up 30 study center US Europe may participate . Safety assess study documentation AEs , clinical laboratory test , physical examination , vital sign measurement , electrocardiogram ( ECGs ) , Eastern Cooperative Oncology Group ( ECOG ) performance status . Adverse event special interest ( AESI ) collect reviewed manner consistent serious adverse event reporting procedure .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>1 . Has histologically cytologically confirm triple negative breast carcinoma either metastatic ( stage IV TNM classification ) locally recurrent amenable local curative treatment . 2 . Evidence measurable , locally recurrent metastatic disease base image study within 28 day first dose study drug . 3 . Has receive least 1 , 2 , prior line systemic therapy locally recurrent and/or metastatic disease . 4 . If patient history treat asymptomatic CNS metastasis eligible , provide meet follow criterion : Patient measurable disease outside CNS ; Patient metastases midbrain , pons , medulla spinal cord ; Patient corticosteroid therapy CNS disease ( anticonvulsant stable dose allow ) ; Patient wholebrain radiation within 6 week prior study enrollment ; Patient stable CNS disease demonstrate least 4 week stability last intervention scan study screen scan 5 . ECOG performance status 0 1 . 6 . Has acceptable , applicable laboratory parameter . 7 . Female subject must pregnant ; willing use 2 method birth control/abstinence applicable 120 day last dose study drug 8 . Experienced resolution toxic effect ( ) recent prior anticancer therapy Grade &lt; 1 ( except alopecia neuropathy ) . 9 . Able understand give write informed consent comply study procedure . 1 . Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . 2 . Active autoimmune disease include active diverticulitis , symptomatic peptic ulcer disease , colitis , inflammatory bowel disease require systemic treatment past 2 year 3 . Previously treat PD1/PDL1blocking antibody histone deacetylase inhibitor 4 . History current evidence condition , therapy , laboratory abnormality might confound result study , interfere patient 's participation full duration study , best interest patient participate , opinion treat Investigator , include , limited : History immune deficiency autoimmune disease ; Myocardial infarction arterial thromboembolic event within 6 month prior screen severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease , QTc interval &gt; 470 msec ; Uncontrolled hypertension diabetes mellitus ; Another know malignancy progress require active treatment ; Active infection require systemic therapy ; Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . 5 . Any contraindication oral agent significant nausea vomiting , malabsorption , significant small bowel resection , opinion investigator , would preclude adequate absorption . 6 . Received live vaccine within 30 day first dose treatment . 7 . Prior anticancer monoclonal antibody ( mAb ) within 4 week prior enrollment recover AEs due mAb agent administer 4 week earlier . 8 . Prior chemotherapy within 4 week , target small molecule therapy radiation therapy within 2 week prior enrollment , recover ( i.e. , â‰¤Grade 1 enrollment ) AEs due previously administer agent . 9 . Received transfusion blood product administration colony stimulate factor within 4 week prior first dose treatment . 10 . Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study drug . 11 . Currently receive treatment agent list prohibited medication list 12 . If female , pregnant , breastfeeding , expect conceive start screen visit 120 day last dose study drug . 13 . Known history human immunodeficiency virus ( HIV ) ( HIV 1/2 antibody ) . 14 . Known active hepatitis B hepatitis C 15 . Allergy benzamide inactive component entinostat . 16 . History allergy active inactive ingredient atezolizumab . 17 . Known psychiatric substance abuse disorder would interfere cooperation requirement study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>